

## THE EVOLVING PARADIGM: Advances in the Chemotherapeutic Management of Metastatic Colorectal Cancer

This activity is supported through an unrestricted educational grant from Roche Laboratories.

Release Date: October, 2003

Expiration Date: October 31, 2004

### Target Audience

This educational activity is intended for physicians and nurses involved in the management of patients with cancer.

### Overview

This article provides an overview of conventional and evolving medical therapies for patients with metastatic colorectal cancer.

### Learning Objectives

After completion of this activity, participants should be able to:

- > Describe the role of various classes of

chemotherapeutic agents, including fluoropyrimidines, topoisomerase I inhibitors, and platinum agents, approved for the management of patients with metastatic colorectal cancer

- > Describe the evolution of treatment strategies for patients with metastatic colorectal cancer
- > Discuss the advantages and disadvantages of newer combination regimens
- > Review current data on tumor-targeted therapies

### Designation of Credit – Physicians

The Dannemiller Memorial Educational Foundation designates this educational

activity for a maximum of **1.5 category 1 credits** toward the American Medical Association Physician's Recognition Award.

### Accreditation/Designation of Credit – Nurses

The Dannemiller Memorial Educational Foundation is an approved provider of the California Board of Registered Nursing. Provider approved by the California Board of Registered Nursing, Provider Number 4229, for **1.5 contact hours**.

### Registration

The program can be accessed via the web at [www.oncologyse.com](http://www.oncologyse.com). Click on the CME button on the left and look for this program.

## FROM TARGETS TO THERAPY: Novel Drugs in Advanced Clinical Trials

This CE activity is supported by an educational grant from Millennium Pharmaceuticals, Inc.

Release Date: November 30, 2003

Expiration Date: November 30, 2004

### Program Overview

Drugs for the following novel targets are currently in advanced clinical trials: the proteasome, mammalian target of rapamycin (mTOR), and Bcl-2. This symposium will discuss the molecular targets, mechanisms of action, and potential clinical application of these drugs.

### Target Audience

Oncologists, hematologists, pharmacists, nurses and other health care professionals who manage and treat patients with solid tumors or hematologic malignancies.

### Learning Objectives

- > Recognize how new technology is used to identify potential therapeutic targets in cancer

- > Describe the molecular mechanism of therapeutic targets and how they impact cancer development and proliferation
- > Discuss how novel targeted therapies impact these targets
- > Identify the safety and efficacy of cancer therapies and how recent clinical trial results will impact optimal patient care

### Credit Designation

The University of Nebraska Medical Center, Center for Continuing Education designates this educational activity for a **minimum of 3 category 1 credits toward the AMA Physician's Recognition Award**. Each physician should claim only those credits that he/she actually spent in the activity.

**This program has been assigned the Universal Program Number 247-000-03-015-H01 and approved for 3 contact hours (0.3 CEUs).**



This educational activity has been approved by the New York State Nurses Association, an accredited provider approved by the American Nurses Credentialing Center's Commission on Accreditation. It has been assigned approval code 5SRQ23-03.

### Registering Information

Oncology Associates will send this CE in the mail to your practice. If you do not receive this workbook and virtual symposium on CD-ROM, please contact Oncology Associates at **888-732-7352**.